Summary Marketline's Taisho Pharmaceutical Holdings Co Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Taisho Pharmaceutical Holdings Co Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances since January2007. Marketline's Company Mergers & Acquisitions (M&A), ...
Summary Standard Chem & Pharm Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Standard Chem & Pharm Co Ltd (SCP) manufactures and markets pharmaceutical and healthcare products. The company's product offerings include pharmaceuticals, supplements, and API. ...
Summary Taisho Pharmaceutical Holdings Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Taisho Pharmaceutical Holdings Co Ltd (Taisho Pharmaceutical) develops, manufactures and markets self-medication drugs and prescription pharmaceuticals. The company's sel...
* Earnings fell c6% yoy in Q3 FY23. Earnings stood at BDT 4,283 mn (BDT 4.83) in Q3 FY23 against BDT 4,570 mn (BDT 5.15) in Q3 FY22. This rise was mainly driven by 306 bps decline in gross margin, 230 bps opex to sales rise and 221 bps effective tax rate rise. In 9M FY23, earnings stood at BDT 14,909 mn (BDT 16.82) against BDT 14,211 mn (BDT 16.03) in 9M FY22, implying c5% yoy growth. * Revenue rose c8% yoy in Q3 FY23. Revenue stood at BDT 15,887 mn in Q3 FY23 against BDT 14,650 mn in ...
Feature article: 2022 Pharma Statistics - 8.7% growth – but worrying signs An efficient reporting system has seen all the listed multinational pharmaceutical companies announcing results for 2022, which has given us the opportunity to update our industry statistics and drug database. This report provides the first snapshot of the global and US rankings of the top 20 drug companies for 2022. 2022 was characterised by 8.7% underlying growth, offset by a large forex impact (-12%), due to USD stren...
* Consolidated earnings rose c10% yoy in Q2 FY23. SQURPHARMA’s EPS in Q2 FY23 stood at BDT 5.78 which is in line with expected EPS of BDT 5.76. This growth in earnings was mainly driven by c14% growth in revenue and c32% growth in other income. However, the drivers were slightly offset by 44 bps gross margin dip, 65 bps Opex/Sales rise, and c3% decline in associate’s earnings. * Consolidated net revenue rose c14% yoy in Q2 FY23. SQURPHARMA generated a c13% yoy growth in local sales and ...
* Sector revenue rose c4% yoy in Q1 FY23. Single digit industry revenue growth in Q1 FY23 can be attributed to the base effect of Q1 FY22. In Q1 FY22, as the economy resumed and doctors returned to their practices, the sales of prescription drugs rose which led to c. 20% revenue growth that quarter. In Q1 FY23, ACME, Navana, Renata, Square significantly outperformed the industry. ACI Pharma and Beacon significantly underperformed the industry as their yoy growth rates fell by c19% and c11% r...
* EPS rose c10% yoy in Q1 FY23. EPS in Q1 FY23 stood at BDT 6.20 against BDT 5.64 reported in Q1 FY22. Major drivers include 8% revenue growth, BDT 399mn foreign exchange gain and 39 bps rise in gross margin. If earnings were adjusted for foreign exchange gain, earnings growth would stand at c2% yoy. Associates — which contributed c9% to total earnings — grew c18% yoy, driven mostly by SQUAREFASHION’s c61% yoy earnings growth. * Revenue rose c8% in Q1 FY23. Revenue rose to BDT 16,070 mn...
* Earnings growth +14% yoy in FY22, -8% yoy in Q4 FY22. EPS in Q4 FY22 stood at BDT 4.48 against BDT 4.87 in Q4 FY21, implying an 8% de-growth. In FY22, SQURPHARMA reported EPS BDT 20.51 against BDT 17.99 in FY21, implying a 14% growth. * Actual EPS of BDT 20.51 in FY22 fell short of our estimate of BDT 21.1. We believe this shortfall occurred may be the result of SQURPHARMA failing to implement the measures required to avail the benefit of having corporate tax lowered to 20.5% from 22....
Hardman & Co Research Hardman & Co Life Sciences Research: Long-term pharmaceutical industry cost and EBIT analysis 10-Jun-2022 / 01:00 GMT/BST Hardman & Co Life Sciences Research: Long-term pharmaceutical industry cost and EBIT analysis Financial information from over 100 multinational drug companies, involving over 70,000 data points, have been accumulated over the past 35 years to create a pharmaceutical database. All our data (sales, COGS, SG&A, R&D and other income) have been derived from annual reports, regulatory filings and company presentations, and then analysed, wherever ...
The Japanese stock market is in an interesting phase where the Bank of Japan is supporting the bond market rather than the stock market. While this phase lasts, the dollar should remain above ¥120/$ and perhaps strengthen further against the yen. This report looks at what this phase might mean for the Japanese stock market as a whole, and for stock selection. The PSA Focus List has also been updated.
The independent financial analyst theScreener just awarded an improved star rating to CHUGAI PHARM. (JP), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 2 out of 4 possible stars. With regard to its market behaviour, it remains unchanged and can be qualified as moderately risky. theScreener considers that these elements allow slightly upgrading its rating to Neutral. As of the analysis date March 18, 2022, th...
ASTELLAS PHARMA (JP), a company active in the Pharmaceuticals industry, reduced its market risk and raised its general evaluation. The independent financial analyst theScreener awarded an improved star rating to the company, which now shows 3 out of 4 possible stars; its market behaviour has improved and can be considered as defensive. theScreener believes that this new assessment merits an overall rating upgrade to Slightly Positive. As of the analysis date February 22, 2022, the closing price ...
Although the Japanese economy, politics and stock market seem to be where they were this time last year, there is a seismic shift going on in the way the Japanese stock market behaves that could make investing in Japan in 2022 quite different to previous years. We look at how and why this shift has taken place and what it means for investing in Japan in the coming year.
* SQUARE reported BDT 5.6 EPS (NPAT BDT 4,997mn) in Q1 FY22, implying c27% growth over BDT 4.4 EPS (NPAT BDT 3,932mn) in Q1 FY21. The growth in earnings is driven by c18% YoY growth in top-line revenue and substantial growth in the textiles associates. In addition, YoY lower effective tax rate by 274 bps due to tax cut in FY21 national budget, further contributed to the bottom line. * Revenue reached BDT 14,877mn in Q1 FY22, implying c18% YoY growth. The local sales jumped up by c19% Y...
* EPS of the company stood at BDT 18.0 (NPAT BDT 15,940mn) in FY21, implying c19% growth over BDT 15.1 (NPAT BDT 13,355mn) in FY20. The annual earnings of the company is in line with our expected EPS of BDT 18.3 in FY21. * Q4 FY21 EPS stood at BDT 4.86 against BDT 3.22 in Q4 FY20, thus implying c51% earnings growth yoy. * SQUARE declared BDT 6.0/share cash dividend (c33% pay-out) in FY21 against BDT 4.5/share cash dividend (c30% pay-out) in FY20. The dividend declaration for FY21...
Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
Pelham Smithers presents his strategy for Q3 2021 and the changes to PSA's stock Focus List Table of Contents Overview 3 Background 4 Valuations & Value 5 The Case for “Muddle Through” 6 Consumer Spending 7 The Labour Market 7 The Currency and the Carry Trade 8 The BoJ and Policy 9 Japan’s Stuttering Economy 10 Stock Performance and Earnings Expectations 12 Catalysts: Digital Transformation, Semiconductors, Price Hikes ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.